Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients

Clinical and Diagnostic Laboratory Immunology

Volumn 3, Issue 3, 1996, Pages 363-364

  Tedeschi, R ^a   Dillner, J ^b   De Paoli, P ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TRANSACTIVATOR PROTEIN;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030014634     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.3.3.363-364.1996     Document Type: Article

References (20)

1. Carey, M., J. Kolman, D. A. Katz, L. Gradoville, L. Barberis, and G. Miller. 1992. Transcriptional synergy by Epstein-Barr virus transactivator ZEBRA. J. Virol. 66:4803-4813.
2. Cheng, H. M., Y. T. Foong, C. K. Sam, U. Prasad, and J. Dillner. 1991. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J. Clin. Microbiol. 29:2180-2186.
3. Dillner, J., L. Dillner, G. Utter, C. Eklund, A. Rotola, S. Costa, and D. Diluca. 1990. Mapping of linear epitopes of human papilloma virus type 16: the L1 and L2 open reading frames. Int. J. Cancer 45:529-535.
4. Dillner, J., and B. Kallin. 1988. The Epstein-Barr virus proteins. Adv. Cancer Res. 50:95-151.
5. Dillner, J., R. Szigeti, W. Henle, G. Henle, R. A. Lerner, and G. Klein. 1987. Cellular and humoral immune responses to synthetic peptides deduced from the amino-acid sequences of Epstein-Barr virus encoded proteins in EBV-transformed cells. Int. J. Cancer 40:455-460.
6. Foong, Y. T., H. M. Cheng, C. K. Sam, J. Dillner, W. Hinderer, and U. Prasad. 1990. Serum and salivary IgA antibodies against a defined epitope of the Epstein Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int. J. Cancer 45:529-535.
7. Houghten, R. A. 1985. General method for the rapid solid phase synthesis of large number of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82:5131-5153.
8. Joab, I., J. C. Nicolas, G. Schwaab, G. de The, B. Clausse, M. Perricaudet, and Y. Zeng. 1991. Detection of anti Epstein-Barr virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int. J. Cancer 48:647-649.
9. Joab, I., H. Triki, J. de Saint Martin, M. Perricaudet, and J. C. Nicolas. 1991. Detection of anti Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 163:53-56.
10. Klein, G. 1989. Latency and transformation: the strategy of EBV. Cell 58: 5-8.
11. Lai, P. K., X. Li, and D. J. Volski. 1989. Induction of EBV in lymphoblastoid cells by HIV1. Int. J. Cancer 43:1104-1111.
12. Lennette, E. T. 1991. The Epstein-Barr virus, p. 847-852. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, D.C.
13. Mathew, A., H. M. Cheng, C. K. Sam, I. Joab, U. Prasad, and C. A. Cochet. 1994. High incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol. Immunother. 38:68-70.
14. Middledorp, J. M., and R. H. Meloen. 1988. Epitope mapping of EBV major capsidic protein using systematic synthesis of overlapping oligopeptides. J. Virol. Methods 21:147-159.
15. Miller, G. 1990. The switch between latency and replication of Epstein-Barr virus. J. Infect. Dis. 161:833-344.
16. Pearson, G. R. 1988. Elisa tests and monoclonal antibodies for EBV. J. Virol. Methods 21:97-104.
17. Rahman, A., L. A. Kingsley, and M. Breinig. 1989. Enhanced antibody response to Epstein-Barr virus in HIV-infected homosexual men. J. Infect. Dis. 159:472-479.
18. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
19. Sumaya, C. V., R. N. Boswel, Y. Ench, D. L. Kisner, E. M. Hersh, J. M. Reuban, and P. W. A. Mansell. 1986. Enhanced serological and virological findings of EBV in patients with AIDS and ARC. J. Infect. Dis. 154:864-870.
20. Tedeschi, R., Y. T. Foong, H. M. Cheng, P. De Paoli, T. Lethinen, T. Elfborg, and J. Dillner. 1995. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J. Gen. Virol. 76:1393-1400.